Myriad Genetics expands cancer detection test availability By Investing.com

Myriad Genetics expanded access to its Precise MRD test for breast, colorectal and renal cancers, reaching more than 6 million U.S. patients, and published MONITOR-Breast results showing 93% ctDNA detection at baseline and 100% specificity for predicting pathological complete response. The company also reported Q1 2026 revenue of $200.4 million versus $202.39 million expected and an adjusted EPS loss of $0.09, wider than the $0.0706 loss forecast. Additional catalysts include the launch of Prolaris + AI, a new CTO appointment, and rising short interest, while the stock trades at $4.50 versus a 52-week high of $8.59.

Analysis

The setup is less about this single clinical update and more about whether MYGN can turn “good science” into a repeatable commercial wedge before the market loses patience. In MRD, the economic moat usually comes from workflow integration and reimbursement friction, not assay sensitivity alone; that means the real upside is a multi-quarter adoption curve in institutions already running longitudinal oncology programs, while the risk is that superior data still takes too long to convert into volume.

The second-order issue is competitive positioning versus larger liquid-biopsy platforms and hospital-developed testing alternatives. If the company can prove MRD changes management earlier in the treatment pathway, it can pull testing forward from a niche surveillance tool into a decision-support layer, which increases test cadence and basket size; if not, the product remains a low-frequency add-on with limited revenue leverage despite strong margins. That matters because the market is implicitly asking whether revenue growth can outrun fixed-cost drag before cash burn forces another reset.

The selloff context suggests expectations are already compressed, but short interest and mixed execution make this a classic “show-me” name over the next 1-2 quarters. The contrarian read is that the market may be underestimating how quickly a clinically credible MRD franchise can re-rate a subscale diagnostics company if reimbursement and utilization both improve; however, the flip side is that one more miss on top-line conversion would likely overwhelm any incremental clinical enthusiasm.

Key Decisions for Investors

• Buy MYGN on weakness only, using a 4-8 week window: the risk/reward improves if the stock holds recent lows while the market digests the MRD data. Use a tight stop below the post-earnings support level because this is still a fundamentals-first name with limited margin for execution error.
• Express a pair trade: long MYGN vs short a higher-beta liquid biopsy peer basket over 1-3 months if you believe MRD data will drive relative multiple expansion before revenue inflects. The trade works best if investor attention shifts from quarterly misses to clinical differentiation.
• If liquidity allows, sell out-of-the-money puts on MYGN into post-news volatility for a 30-45 day horizon. The thesis is that downside is increasingly valuation-anchored, while upside needs only modest proof of adoption to squeeze shorts.
• Avoid chasing a straight long until there is evidence of reimbursement or order-flow traction in the next 1-2 quarters. Without that, the stock risks becoming a “data good, business slow” trap.